Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Forecast Report Coverage

Expert Market Research's “Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of human immunodeficiency virus type 1 (HIV-1) infection. It projects the future incidence and prevalence rates of human immunodeficiency virus type 1 (HIV-1) infection cases across various populations. The study covers age, gender, and type as major determinants of the human immunodeficiency virus type 1 (HIV-1) infection population. The report highlights patterns in the prevalence of human immunodeficiency virus type 1 (HIV-1) infection over time and projects future trends based on multiple variables.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Understanding: Disease Overview

Human immunodeficiency virus type 1 (HIV-1) infection is a chronic viral infection that targets the immune system, specifically CD4+ T cells, leading to progressive immune suppression. It is primarily transmitted through unprotected sexual contact, blood exposure, and from mother to child during pregnancy, childbirth, or breastfeeding. Without treatment, HIV-1 advances to acquired immunodeficiency syndrome (AIDS), characterized by opportunistic infections and malignancies. The disease remains a major global public health concern, with significant morbidity and mortality, although early diagnosis and continuous care have improved long-term patient outcomes.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Perspective

The human immunodeficiency virus type 1 (HIV-1) infection epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the human immunodeficiency virus type 1 (HIV-1) infection epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for human immunodeficiency virus type 1 (HIV-1) infection and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the World Health Organization and UNAIDS, approximately 40.8 million people were living with HIV globally in 2024, with 1.3 million new infections annually, representing predominantly HIV-1 burden.
• Human immunodeficiency virus type 1 (HIV-1) represents a broad spectrum of subtypes and recombinant forms. As per Hemelaar J et al., 2023, HIV-1 accounts for over 95% of global HIV infections, with subtype C contributing 46-48% worldwide.
• According to World Health Organization, adults account for 96% of cases, and females represent 53% globally.
• As per a 2022 review article published in the Frontiers in Immunology, out of 38 million individuals affected with human immunodeficiency virus in 2020, 52% of the patient population was female.
• By 2024, approximately 40.8 million people were living with HIV globally, with nearly 65% of cases concentrated in the WHO African Region, according to World Health Organization.

Read more about this report - Request a Free Sample

Country-wise Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology

The human immunodeficiency virus type 1 (HIV-1) infection epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of human immunodeficiency virus type 1 (HIV-1) infection across developed countries reflects both sustained disease burden and improving management outcomes. According to HIV.gov, approximately 1.2 million individuals are living with HIV in the United States, with about 31,800 new infections reported in 2022, largely representing HIV-1 cases. Meanwhile, as per Terrence Higgins Trust, the United Kingdom continues to observe a stable but aging HIV population with ongoing disparities among key groups. These trends indicate gradual progress in diagnosis and care, while highlighting the continued need for targeted prevention and treatment strategies.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Treatment Overview

Management of human immunodeficiency virus type 1 (HIV-1) infection relies on combination antiretroviral therapy (ART), which suppresses viral replication, restores immune function, and prevents disease progression. Standard treatment includes integrase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors. Lifelong adherence to ART is essential to maintain viral suppression and reduce transmission risk. Advances in long-acting injectable therapies and simplified regimens are improving patient compliance. Preventive strategies such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) further support disease control and reduce new infections globally.

Key Questions Answered

• What are the key findings of human immunodeficiency virus type 1 (HIV-1) infection epidemiology in the 8 major markets?
• What will be the total number of patients with human immunodeficiency virus type 1 (HIV-1) infection across the 8 major markets during the forecast period?
• What was the country-wise human immunodeficiency virus type 1 (HIV-1) infection epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of human immunodeficiency virus type 1 (HIV-1) infection patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of human immunodeficiency virus type 1 (HIV-1) infection during the forecast period of 2026-2035?
• What are the currently available treatments for human immunodeficiency virus type 1 (HIV-1) infection?
• What are the disease risks, signs, symptoms, and unmet needs of human immunodeficiency virus type 1 (HIV-1) infection?

Scope of the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of human immunodeficiency virus type 1 (HIV-1) infection based on several factors.
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The human immunodeficiency virus type 1 (HIV-1) infection report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Human Immunodeficiency Virus (HIV1) Infection Market

Human Immunodeficiency Virus (HIV 1) Infection Drug Pipeline